Search results
Amphastar maintains stock target on AMP-008 FDA approval By Investing.com
Investing.com· 18 hours agoOn Thursday, Piper Sandler confirmed its Overweight rating and a $71.00 stock price target for...
Sol-Gel Technologies Ltd. (SLGL) Reports Q1 Loss, Lags Revenue Estimates
Zacks· 4 days agoThis quarterly report represents an earnings surprise of -53.33%. Over the last four quarters, the company has surpassed consensus EPS estimates two times. , which belongs ...
This Unpopular Dividend Stock Is a Buy
The Motley Fool via AOL· 23 hours agoBMS is dealing with the loss of patent protection...s why contrarian investors may want to scoop up this unpopular dividend stock right now. Bristol...
Here's Why You Should Retain Walgreens Boots (WBA) For Now
Zacks via Yahoo Finance· 19 hours agoOf late, increased reimbursement pressure and generic drug cost inflation have been hampering...
Hims & Hers will sell knock-off Ozempic for $199 — and it won’t be approved by FDA
NY Post via Yahoo Finance· 15 hours ago“We have a certain degree of exclusivity with that...GLP-1 semaglutide far exceeds the current...
Cannabis Meets Prescription Drugs, Steroids And Ketamine In Schedule III: What It Means, Key Stocks...
Benzinga· 6 days agoPresident Joe Biden's administration is moving to reschedule cannabis from Schedule I to Schedule...
HIMS Stock Alert: Hims & Hers Shares Rocket on Weight Loss Injections
InvestorPlace· 4 days agoHims & Hers has partnered with an undisclosed manufacturer of generic and 503B compounded injectable...
Hims debuts $199 weight-loss shots at 85% discount to Wegovy
Detroit News· 4 days agoIn just a few years, Hims & Hers Health Inc. reached almost $1 billion in sales by making it easy to...
Hims & Hers is getting into the weight-loss drug game — and Wall Street is loving it
INSIDER via Yahoo News· 4 days agoHims & Hers' stock surged more than 30% on Monday in response to the news...brand-name versions —...
Health Care Roundup: Market Talk
The Wall Street Journal· 7 days agoDeutsche Bank raises its rating on the Swiss drug company’s stock to hold from sell. “After ruminating post-Q1 whether Roche could salvage ...
